Meeting
2017 ASCO Annual Meeting
The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).
Authors
Jeanne Tie
Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
Jeanne Tie , Joshua Cohen , Yuxuan Wang , Lu Li , Isaac Kinde , Hany Elsaleh , Rachel Wong , Suzanne Kosmider , Desmond Yip , Margaret Lee , Ben Tran , Matthew E. Burge , David Goldstein , Madhu Sudan Singh , Luis A. Diaz Jr., Cristian Tomasetti , Nickolas Papadopoulos , Kenneth W. Kinzler , Bert Vogelstein , Peter Gibbs
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3521)
DOI
10.1200/JCO.2017.35.15_suppl.3521
Abstract #
3521
Poster Bd #
144
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Using circulating tumor DNA (ctDNA) to predict surgical outcome and postoperative recurrence following neoadjuvant chemoradiation (CRT) for borderline resectable/locally advanced rectal cancer (LARC).
First Author: Susan G.R. McDuff
Poster
2024 ASCO Annual Meeting
Longitudinal circulating tumor DNA monitoring in predicting response to short-course neoadjuvant radiotherapy in locally advanced rectal cancer: Data from a phase III clinical trial (UNION).
First Author: Zhenyu Lin
Poster
2023 ASCO Annual Meeting
Predictive value of tumor-infiltrating lymphocyte (TIL) dynamics in the tumor microenvironment (TME) during preoperative chemoradiotherapy (CRT) on pathologic complete response (pCR) in microsatellite-stable (MSS) locally advanced rectal cancer (LARC).
First Author: Mitsuho Imai
Poster
2022 ASCO Annual Meeting
Preoperative chemoradiotherapy with capecitabine with or without temozolomide in patients with locally advanced rectal cancer: A prospective, randomized phase 2 study stratified by MGMT (O6-methylguanine DNA methyltransferase) status: KCSG-CO17-02.
First Author: Chung Ryul Oh